Rituximab maintenance overcomes the negative prognostic factor
of obesity in CLL: Subgroup analysis of the international
randomized AGMT CLL-8a mabtenance trial

J 2019

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial

EGLE, Alexander; Thomas MELCHARDT; Petra OBRTLIKOVA; Lukas SMOLEJ; Tomas KOZAK et al.

Základní údaje

Originální název

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial

Autoři

Vydání

Cancer Medicine, Houston, John Wiley & Sons Ltd. 2019, 2045-7634

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Rakousko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.491

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00110357

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

BMI; CLL; maintenance; obesity; rituximab

Štítky

14110212, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 5. 2020 09:55, Mgr. Tereza Miškechová

Anotace

V originále

No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL-8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab-containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375mg/m(2) q3 months for 2years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non-obese, P=0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P=0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39months median PFS, P=0.03). However, in the rituximab maintenance group the outcome for obese vs non-obese was not different (P=0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect.

Citovat

EGLE, Alexander; Thomas MELCHARDT; Petra OBRTLIKOVA; Lukas SMOLEJ; Tomas KOZAK; Michael STEURER; Johannes ANDEL; Sonja BURGSTALLER; Eva MIKUSKOVA; Liana GERCHEVA; Thomas NOSSLINGER; Tomas PAPAPJIK; Miriam LADICKA; Michael GIRSCHIKOFSKY; Mikulas HRUBISKO; Ulrich JAGER; Daniela VOSKOVA; Martin PECHERSTORFER; Eva KRALIKOVA; Christina BURCOVEANU; Emil SPASOV; Andreas PETZER; Georgi MIHAYLOV; Julian RAYNOV; Horst OEXLE; August ZABERNIGG; Emilia FLOCHOVA; Stanislav PALASTHY; Olga STEHLÍKOVÁ; Michael DOUBEK; Petra ALTENHOFER; Lukas WEISS; Teresa MAGNES; Lisa PLEYER; Anton KLINGLER; Jiří MAYER a Richard GREIL. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. Cancer Medicine. Houston: John Wiley & Sons Ltd., 2019, roč. 8, č. 4, s. 1401-1405. ISSN 2045-7634. Dostupné z: https://doi.org/10.1002/cam4.1980.

@article{1548863,
   author = {Egle, Alexander and Melchardt, Thomas and Obrtlikova, Petra and Smolej, Lukas and Kozak, Tomas and Steurer, Michael and Andel, Johannes and Burgstaller, Sonja and Mikuskova, Eva and Gercheva, Liana and Nosslinger, Thomas and Papapjik, Tomas and Ladicka, Miriam and Girschikofsky, Michael and Hrubisko, Mikulas and Jager, Ulrich and Voskova, Daniela and Pecherstorfer, Martin and Kralikova, Eva and Burcoveanu, Christina and Spasov, Emil and Petzer, Andreas and Mihaylov, Georgi and Raynov, Julian and Oexle, Horst and Zabernigg, August and Flochova, Emilia and Palasthy, Stanislav and Stehlíková, Olga and Doubek, Michael and Altenhofer, Petra and Weiss, Lukas and Magnes, Teresa and Pleyer, Lisa and Klingler, Anton and Mayer, Jiří and Greil, Richard},
   article_location = {Houston},
   article_number = {4},
   doi = {https://doi.org/10.1002/cam4.1980},
   keywords = {BMI; CLL; maintenance; obesity; rituximab},
   language = {eng},
   issn = {2045-7634},
   journal = {Cancer Medicine},
   title = {Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial},
   url = {http://dx.doi.org/10.1002/cam4.1980},
   volume = {8},
   year = {2019}
}

TY  - JOUR
ID  - 1548863
AU  - Egle, Alexander - Melchardt, Thomas - Obrtlikova, Petra - Smolej, Lukas - Kozak, Tomas - Steurer, Michael - Andel, Johannes - Burgstaller, Sonja - Mikuskova, Eva - Gercheva, Liana - Nosslinger, Thomas - Papapjik, Tomas - Ladicka, Miriam - Girschikofsky, Michael - Hrubisko, Mikulas - Jager, Ulrich - Voskova, Daniela - Pecherstorfer, Martin - Kralikova, Eva - Burcoveanu, Christina - Spasov, Emil - Petzer, Andreas - Mihaylov, Georgi - Raynov, Julian - Oexle, Horst - Zabernigg, August - Flochova, Emilia - Palasthy, Stanislav - Stehlíková, Olga - Doubek, Michael - Altenhofer, Petra - Weiss, Lukas - Magnes, Teresa - Pleyer, Lisa - Klingler, Anton - Mayer, Jiří - Greil, Richard
PY  - 2019
TI  - Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial
JF  - Cancer Medicine
VL  - 8
IS  - 4
SP  - 1401-1405
EP  - 1401-1405
PB  - John Wiley & Sons Ltd.
SN  - 20457634
KW  - BMI
KW  - CLL
KW  - maintenance
KW  - obesity
KW  - rituximab
UR  - http://dx.doi.org/10.1002/cam4.1980
L2  - http://dx.doi.org/10.1002/cam4.1980
N2  - No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL-8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab-containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375mg/m(2) q3 months for 2years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non-obese, P=0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P=0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39months median PFS, P=0.03). However, in the rituximab maintenance group the outcome for obese vs non-obese was not different (P=0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect.
ER  -

EGLE, Alexander; Thomas MELCHARDT; Petra OBRTLIKOVA; Lukas SMOLEJ; Tomas KOZAK; Michael STEURER; Johannes ANDEL; Sonja BURGSTALLER; Eva MIKUSKOVA; Liana GERCHEVA; Thomas NOSSLINGER; Tomas PAPAPJIK; Miriam LADICKA; Michael GIRSCHIKOFSKY; Mikulas HRUBISKO; Ulrich JAGER; Daniela VOSKOVA; Martin PECHERSTORFER; Eva KRALIKOVA; Christina BURCOVEANU; Emil SPASOV; Andreas PETZER; Georgi MIHAYLOV; Julian RAYNOV; Horst OEXLE; August ZABERNIGG; Emilia FLOCHOVA; Stanislav PALASTHY; Olga STEHLÍKOVÁ; Michael DOUBEK; Petra ALTENHOFER; Lukas WEISS; Teresa MAGNES; Lisa PLEYER; Anton KLINGLER; Jiří MAYER a Richard GREIL. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial. \textit{Cancer Medicine}. Houston: John Wiley \&{} Sons Ltd., 2019, roč.~8, č.~4, s.~1401-1405. ISSN~2045-7634. Dostupné z: https://doi.org/10.1002/cam4.1980.

Přehled o publikaci